Skip to main content
This block is broken or missing. You may be missing content or you might need to enable the original module.
Home

Main sub menu

  • Investors
  • Careers
    • Working at Recipharm
    • The Recipharm story
    • Meet our employees
    • Current vacancies
  • Contact
    • Contact us
    • Development services contacts
    • Manufacturing services contacts
    • Locations
      • France
        • Fontaine
        • Kaysersberg
        • Monts
        • Pessac
      • Germany
        • Monheim
        • Wasserburg
        • Zwickau
      • India
        • Bengaluru
        • Karnal / Paonta Sahib
      • Israel
        • Ness Ziona
      • Italy
        • Brescia
        • Lainate
        • Masate
        • Paderno Dugnano
        • Pianezza
      • Portugal
        • Odivelas
        • Queluz
      • Spain
        • Parets
        • Leganés
      • Sweden
        • Höganäs
        • Stockholm city (HQ)
        • Karlskoga
        • Solna
        • Strängnäs
        • Uppsala
        • Uppsala Development
      • UK
        • Cramlington
        • Holmes Chapel
        • Queenborough
        • King’s Lynn
      • USA
        • Research Triangle Park

Main navigation

  • Development
    • Drug substance
    • Drug product
    • Analytical chemistry
    • Clinical trial material (CTM)
  • Manufacturing
    • Solids
    • Semi-solids
    • Liquids
    • Inhalation
    • Injectables
    • Ophthalmics
  • Solutions
    • Recipharm Analytical Solutions™
    • Recipharm Inhalation Solutions™
    • Recipharm Pathway to Clinic®
    • Serialisation
  • Bespak
  • Learn
  • Press & events
    • Press
    • Events
    • Reports
    • Insights
  • Our story
    • Recipharm in brief
    • Business model
    • Sustainability
    • Company history

Press & events

What's happening?

Stay updated on our latest news and events.

Press and Event

  • Press
  • Events
  • Reports
  • Insights
Displaying 31 - 40 of 406

Subscribe

Press

Recipharm doubles EBIT and expects second quarter results to be stronger than analyst consensus

2020.07.13 Read more

Press

Change in the total number of shares and votes in Recipharm AB (publ)

2020.06.30 Read more

Press

Recipharm announces final result of the oversubscribed rights issue

2020.06.25 Read more

Press

Recipharm announces the preliminary outcome of the oversubscribed rights issue

2020.06.24 Read more

Press

Recipharm publishes prospectus

2020.06.04 Read more

Press

Change in the total number of shares and votes in Recipharm AB (publ)

2020.05.29 Read more

Press

The Board of Directors of Recipharm resolves on a rights issue of approximately SEK 2,017 million and announces the terms

2020.05.27 Read more

Press

Recipharm to present at Jefferies 2020 Virtual Healthcare Conference

2020.05.26 Read more

Press

Recipharm has carried out a directed share issue of 4,524,886 class B shares and is hereby provided with proceeds of SEK around 500 million

2020.05.19 Read more

Press

Recipharm to present at the 2020 UBS Virtual Global Healthcare Conference

2020.05.18 Read more

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »

Footer menu

  • Privacy policy
  • Cookies
  • Website terms
© 2021 Recipharm AB (publ). All rights reserved Stormfors Digitalbyrå